MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Revenue | 47,397 | 46,850 | 65,200 | 73,400 |
| Selling, general and administrative | 38,575 | 39,564 | 39,087 | 40,556 |
| Restructuring | - | - | -4 | -4 |
| Research and development | 4,882 | 4,888 | 4,344 | 5,284 |
| Goodwill impairment | 30,449 | 12,435 | 154,239 | - |
| Cost of revenue | 39,629 | 39,125 | 36,826 | 38,271 |
| Change in estimated fair value of contingent consideration | 140 | - | -178 | -1,195 |
| Total operating expenses | 113,675 | 96,012 | 234,314 | 82,912 |
| Loss from operations | -66,278 | -49,162 | -169,114 | -9,512 |
| Interest income | 3,030 | 3,225 | 7,071 | 7,086 |
| Interest expense | 6,815 | 6,778 | 13,634 | 11,939 |
| Other expense | -4,062 | 24 | 72 | -2,562 |
| Change in payable to related parties pursuant to the tax receivable agreement | - | - | 39 | - |
| Loss before income taxes | -74,125 | -52,691 | -175,644 | -16,927 |
| Income tax benefit | -4,288 | 162 | 311 | -2,435 |
| Net loss | -69,837 | -52,853 | -175,955 | -14,492 |
| Net loss attributable to non-controlling interests | -30,246 | -22,908 | -76,917 | -6,907 |
| Net loss attributable to maravai lifesciences holdings, inc | -39,591 | -29,945 | -99,038 | -7,585 |
| Net loss per class a common share attributable to maravai lifesciences holdings, inc., basic (in usd per share) | -0.27 | -0.21 | -0.7 | -0.05 |
| Net loss per class a common share attributable to maravai lifesciences holdings, inc., diluted (in usd per share) | -0.27 | -0.21 | -0.7 | -0.05 |
| Weighted average number of class a common shares outstanding, basic (in shares) | 144,236,000 | 143,425,000 | 141,555,000 | 135,842,000 |
| Weighted average number of class a common shares outstanding, diluted (in shares) | 144,236,000 | 143,425,000 | 141,555,000 | 135,842,000 |